For additional information on the source of any definition in our glossary, please contact our team via email at [email protected].
Use the Search Field to Find a Term
Neuro-modulation
The physiological process by which a given neuron uses one or more neurotransmitters to regulate diverse populations of neurons. The endocannabinoid system (ECS) is a regulatory system; it regulates other systems in the body, including the brain, the motherboard of the central nervous system. When the ECS is deficient, it has problems regulating the other systems. As opposed to other cannabinoids, CBD is a neuro-modulator.
Over-saturation
When the endocannabinoid system is exposed to too many cannabinoids. This can occur when the user is taking very high doses or increases their dosing too quickly. This can present in increased seizure activity, increased lethargy, or increased medication side-effects. When this happens, it is best to skip some doses to allow the cannabinoids to metabolize out of the body. The process of resetting the ECS is sometimes referred to as “rebooting.”
Sublingual
A method of administering cannabis by placing it under the tongue, where it is absorbed directly into the bloodstream.
Terpene
A large and diverse class of organic compounds, produced by a variety of plants, particularly conifers. They are often strong-smelling.
THC
Tetrahydrocannabinol, the principal psychoactive constituent (or cannabinoid) of the cannabis plant. Reported benefits of THC include pain relief, appetite stimulation, sleep aid, anti-nausea, anti-vomiting, and more.
THC-A
Tetrahydrocannabinol acid is chemically similar to THC but is non-psychoactive. Reported benefits include anti-emetic, anti-inflammatory, anti-proliferative, anti-spasmodic, and neuroprotective. Although it is non-psychoactive, it is a fragile chemical and if it is left in heat, light, or air for too long, it can convert into THC and may cause a high.
THCV (Tetrahydrocannabivarin)
A cannabinoid found in cannabis that is similar to THC but may have different effects, including appetite suppression and potential anti-epileptic properties.
CHRI aims to inform clinical decision-making, product development and public policy related to the therapeutic use of cannabinoids.